BNP Paribas Financial Markets Lowers Stake in Mural Oncology plc (NASDAQ:MURA)

BNP Paribas Financial Markets trimmed its holdings in Mural Oncology plc (NASDAQ:MURA) by 71.0% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 28,048 shares of the company’s stock after selling 68,686 shares during the period. BNP Paribas Financial Markets owned 0.16% of Mural Oncology worth $88,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. BBR Partners LLC acquired a new position in Mural Oncology in the 2nd quarter valued at about $31,000. Rhumbline Advisers acquired a new position in shares of Mural Oncology in the second quarter valued at approximately $34,000. FMR LLC raised its stake in shares of Mural Oncology by 124.7% during the third quarter. FMR LLC now owns 20,580 shares of the company’s stock worth $64,000 after purchasing an additional 11,423 shares during the last quarter. Commerce Bank purchased a new stake in shares of Mural Oncology during the third quarter worth approximately $39,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Mural Oncology during the second quarter worth $70,000. Institutional investors and hedge funds own 80.21% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Mural Oncology in a research note on Monday, November 11th. Raymond James began coverage on shares of Mural Oncology in a research note on Friday, October 4th. They set a “strong-buy” rating and a $18.00 price target on the stock.

Insider Activity

In related news, CFO Adam D. Cutler sold 7,421 shares of the company’s stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $3.41, for a total value of $25,305.61. Following the completion of the transaction, the chief financial officer now directly owns 71,438 shares in the company, valued at approximately $243,603.58. This represents a 9.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Mural Oncology Stock Down 5.9 %

Shares of NASDAQ:MURA opened at $3.19 on Thursday. Mural Oncology plc has a 52-week low of $2.88 and a 52-week high of $6.25. The company has a market capitalization of $54.29 million and a P/E ratio of -0.35. The stock’s fifty day simple moving average is $3.62 and its 200-day simple moving average is $3.39.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.